RESEARCH TRIANGLE PARK, N.C. — Scynexis, a drug discovery and development company, has signed a multi-year research agreement with Merck & Co.

The two firms will work to discover and develop compounds for treatment related to cancer. The companies first began working together under another agreement in 2002.

Financial terms were not disclosed.

Scynexis focuses on chemistry to develop highly targeted compound libraries utilizing proprietary technology.

“Scynexis is pleased to carry on our successful relationship with Merck by collaborating in this new area of research,” said Yves Ribeill, chief executive officer of Scynexis, in a statement.